Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 9/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | MPC2 | O95563 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.53 |
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370792 | 0.99 | PPARG (0.62) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL877848 | 0.91 | PPARG (0.65) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL4622433 | 0.85 | PPARG (0.57) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL4177074 | 0.81 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6896704 | 0.80 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6896700 | 0.78 | PPARG (0.86) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL1592290 | 0.77 | PPARG (0.98) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL6064788 | 0.77 | PPARG (0.98) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL7836834 | 0.77 | FFAR1 (0.56) | PPARGFFAR1PPARA | |
| SCHEMBL4857396 | 0.77 | PPARG (0.56) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-2346498-B1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (DE) | 2017-10-26 | — | — | US | disclosed |
| US-9724322-B2 | 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-08 | — | — | US | disclosed |
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-7015329-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-21 | — | — | US | disclosed |
| US-20060058382-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20060058393-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-05 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20030199557-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | ORTHO-MCNEIL PHARMACEUITCAL, INC. | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PPARG 409/4885CA2 4567/4885MPC2 2148/4885 |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PPARG 409/4885CA2 4567/4885MPC2 2148/4885 |
| US-20060058382-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2981/4885MPC2 214/4885 |
| US-20060058393-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2981/4885MPC2 214/4885 |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2731/4885MPC2 372/4885 |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2981/4885MPC2 214/4885 |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2857/4885MPC2 348/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2731/4885MPC2 372/4885 |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | PPARG 111/4885CA2 1825/4885MPC2 323/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | PPARG 409/4885CA2 4567/4885MPC2 2148/4885 |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | PPARG 3/4885CA2 2712/4885MPC2 80/4885 |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2731/4885MPC2 372/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2857/4885MPC2 348/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2558/4885MPC2 1270/4885 |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885CA2 2731/4885MPC2 372/4885 |
| US-20030199557-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | PPARG 3/4885CA2 2712/4885MPC2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.